# REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors

> **NCT03317327** · PHASE1,PHASE2 · COMPLETED · sponsor: **Oslo University Hospital** · enrollment: 20 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Nivolumab
- **RADIATION:** Radiotherapy (RT)

## Key facts

- **NCT ID:** NCT03317327
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-09
- **Primary completion:** 2022-11-28
- **Final completion:** 2022-11-28
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-06-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03317327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03317327, "REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03317327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*